Table 2.
Univariate and multivariate analysis of predictors for major adverse cardiovascular events (MACE) in patients with diabetes who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Age, years | 1.03 | 0.88–1.32 | 0.25 | |||
| BMI, kg/m2 | 0.98 | 0.87–1.35 | 0.66 | |||
| Hypertension | 1.02 | 0.95–1.42 | 0.91 | |||
| Hyperlipidemia | 0.86 | 0.53–1.21 | 0.42 | |||
| Chronic kidney disease | 1.01 | 0.98–1.09 | 0.56 | |||
| Statin use | 0.91 | 0.62–1.61 | 0.74 | |||
| Insulin | 1.61 | 0.84–4.67 | 0.22 | |||
| ACEIs/ARBs use | 1.03 | 0.82–2.52 | 0.48 | |||
| Number of stents, per case | 1.00 | 0.89–1.12 | 0.96 | |||
| GRACE score | 2.68 | 1.01–4.58 | 0.02 | 2.38 | 1.13–9.65 | 0.01 |
| LVEF,% | 0.78 | 0.71–0.92 | 0.03 | 0.82 | 0.78–0.98 | 0.02 |
| LDL-C, mmol/l | 1.01 | 0.97–1.02 | 0.51 | |||
| Calprotectin level | 1.56 | 1.08–4.62 | 0.01 | 2.11 | 1.14–6.65 | <0.01 |
MACE – major adverse cardiovascular events; PCI – percutaneous coronary intervention; HR – Hazard ratio; 95% CI – 95% confidence interval; BMI – body mass index; ACEIs – angiotensin-converting enzyme inhibitors; ARBs – angiotensin receptor blockers; LVEF – left ventricular ejection fraction; LDL-C – low-density lipoprotein cholesterol; GRACE – Global Registry of Acute Coronary Events.